Practical considerations in ovarian cancer chemotherapy.
Practical considerations in ovarian cancer chemotherapy.
复制标题
DOI：
10.1177/1758834010361333
复制
发表时间：
2010-05-01
影响因子：
4.9
通讯作者：
Morgan, Robert J
中科院分区：
文献类型：
--
作者：
Cristea, Mihaela;Han, Ernest;Morgan, Robert J
尽管治疗取得了进步，上皮性卵巢癌仍然是最致命的妇科恶性肿瘤。标准治疗通常涉及手术肿瘤减灭术和化疗的结合。几十年来，卵巢癌的化疗不断发展，目前涉及静脉铂和紫杉烷化疗的组合。在过去的十年中，已经报道了三项随机 III 期试验，所有试验都证明腹腔化疗与静脉化疗相比具有显着的生存优势。然而，卵巢癌患者腹腔内化疗存在潜在的障碍和争议。在这篇综述中，我们讨论了化疗治疗上皮性卵巢癌的演变和当前的管理注意事项。
Epithelial ovarian cancer remains the most lethal gynecologic malignancy despite advances in treatment. The standard management generally involves a combination of surgical tumor debulking and chemotherapy. Over the decades, chemotherapy for ovarian cancer has evolved and currently involves a combination of intravenous platinum and taxane chemotherapy. Over the past decade, three randomized phase III trials have been reported, and all have demonstrated a significant survival advantage for intraperitoneal compared with intravenous chemotherapy. However, there are potential barriers and controversies related to the administration of intraperitoneal chemotherapy in ovarian cancer patients. In this review, we discuss the evolution and current management considerations of chemotherapy for the treatment of epithelial ovarian cancer.